Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARROW: Standard Versus Pre-emptive Antibiotic Treatment After Whipple's Procedure
NCT05784311Phase 4Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cefuroxime and metronidazole in surgical site infection (SSI) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Rate of clinically relevant organ/space surgical site infection at 90 days. Started Mar 2023; status: recruiting.
02
Drugs
cefuroximemetronidazole
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT05784311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05784311.